You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
FK 866 hydrochloride
Biological Activity for FK 866 hydrochloride
FK 866 hydrochloride is a non-competitive and potent inhibitor of NAMPT (nicotinamide phosphoribosyltransferase, PBEF1) (Ki = 0.3 nM); inhibits NAD biosynthesis. Induces delayed cell death by apoptosis in HepG2 human liver carcinoma cells (IC50 ~1 nM). Induces apoptosis in four different neuroblastoma cell lines; also induces autophagy in SH-SY5Y cells. Potentiates the cytotoxic effects induced by etoposide (Cat. No. 1226) and cisplatin (Cat. No. 2251).
Technical Data for FK 866 hydrochloride
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for FK 866 hydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||2.14||5 with gentle warming|
Preparing Stock Solutions for FK 866 hydrochloride
The following data is based on the product molecular weight 427.97. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.34 mL||11.68 mL||23.37 mL|
|5 mM||0.47 mL||2.34 mL||4.67 mL|
|10 mM||0.23 mL||1.17 mL||2.34 mL|
|50 mM||0.05 mL||0.23 mL||0.47 mL|
Product Datasheets for FK 866 hydrochloride
References for FK 866 hydrochloride
References are publications that support the biological activity of the product.
Travelli et al (2011) Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etop. or cisp. in neuroblastoma cells. J.Pharmacol.Exp.Ther. 338 829 PMID: 21685314
Hasmann et al (2003) FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 63 7436 PMID: 14612543
Galli et al (2008) Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage. ChemMedChem 3 771 PMID: 18247435
If you know of a relevant reference for FK 866 hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: FK 866 hydrochloride, FK 866 hydrochloride supplier, FK866, hydrochloride, Nicotinamide, phosphoribosyltransferase, NMPRTase, inhibitors, inhibits, autophagy, apoptosis, NAD, NAMPT, visfatin, PBEF, Apoptosis, Inducers, Autophagy, 4808, Tocris Bioscience
1 Citation for FK 866 hydrochloride
Citations are publications that use Tocris products. Selected citations for FK 866 hydrochloride include:
Singh et al (2018) Nicotinamide Phosphoribosyltransferase Deficiency Potentiates the Antiproliferative Activity of MTX through Enhanced Depletion of Intracellular ATP. J Pharmacol Exp Ther 365 96 PMID: 29420256
Do you know of a great paper that uses FK 866 hydrochloride from Tocris? Please let us know.
Reviews for FK 866 hydrochloride
There are currently no reviews for this product. Be the first to review FK 866 hydrochloride and earn rewards!
Have you used FK 866 hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cancer Metabolism Poster
Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the main targets for cancer metabolism researchers. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways. These distinct metabolic circuits could provide viable cancer therapeutic targets.